Updated Jan 22. 2021
Thank you: Front Line COVID-19
Critical Care Alliance
What can you do to prevent getting COVID-19?
Dr. Paul Marik, a founding member of the Front Line COVID-19 Critical Care Alliance, takes you through all of the steps you can take to limit your chances getting COVID-19. At the heart of it is the FLCCC Alliance’s I-Mask+ Prophylaxis & Early Outpatient Treatment Protocol. Its components include ivermectin, which has been shown in study after study to prevent COVID-19, and to keep patients who become symptomatic from progressing into more serious COVID-19 illness. Watch and SHARE please!
The FLCCC Alliance
As a group of colleagues with over 200 years of combined experience in Critical Care and Emergency Medicine, as well as long-standing shared interests in developing effective treatments for critical illnesses including sepsis, we, the FLCCC Alliance, formed a working group devoted to creating a treatment protocol against COVID-19 in early March 2020. The protocol we devised, called MATH+, is intended for use in hospitalized patients, with an emphasis on early initiation—as soon as a patient develops the need for supplemental oxygen.
The success of the MATH+ hospital treatment protocol is detailed in the team’s Clinical and Scientific Rationale for the MATH+ Hospital Treatment Protocol for COVID-19 published in the Journal of Intensive Care Medicine in December 2020. The two hospitals that adopted the MATH+ protocol and initiated it early in the treatment of COVID-19 patients (in ICU) averaged only a 5.1% mortality rate, compared with mortality rates reported from other hospitals of between 10–30% during the same time periods, depending on whether corticosteroids were used. Information about the team’s more recent I-MASK+ formula for prophylaxis and early outpatient treatment of COVID-19 can be found here.
We would like to emphasize that the FLCCC Alliance is not opposed to vaccination, and furthermore supports policies such as mask wearing, social distancing, and hand hygiene to prevent the further spread of the SARS-CoV-2 virus. Our treatment proposals are designed, first of all, to mitigate the effects of the pandemic until it is overcome, and to allow for an earlier return to daily life.
My brother in Law – Jeff Larsen- has been diagnosed with Covid Lung Disease! Many times on the edge. many times we have asked for clergy.
Many days we have embraced the miracle of his life ….
Since before Thanksgiving 2020 -we have been as a family – a global family – a Miracle Making – Heart opening experience!
Thank you for your prayers! I believe it is your prayers as well as his incredible team at St. Josephs!
YOU ARE SAVING LIVES when you learn what is written on this page!
Thank you for your prayers! Greg writes an update here: https://www.facebook.com/photo/?fbid=10224558847744627&set=a.2104340934063
Please Watch Dr. Kory
NIH (National Institutes of Health) Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19
Ivermectin is Now a Treatment Option for Health Care Providers!
Jan 14, 2021 – One week after Dr. Paul Marik and Dr. Pierre Kory – founding members of the Front Line Covid-19 Critical Care Alliance (FLCCC) – along with Dr. Andrew Hill, researcher and consultant to the World Health Organization (WHO), presented their data before the NIH Treatment Guidelines Panel, the NIH has upgraded their recommendation and now considers Ivermectin an option for use in COVID-19.
Their recommendation has now been upgraded to the same level as those for widely used monoclonal antibodies & convalescent plasma, which is a “neither for nor against” recommendation. The significance of this change is that the NIH has decided to no longer recommend against the use of ivermectin in the treatment of COVID-19 by the nation’s health care providers. A consequence of this change is that ivermectin has now been made a clear therapeutic option for patients.
MATH+ Hospital Treatment Protocol for COVID-19
Read more here: https://covid19criticalcare.com/math-hospital-treatment/pdf-translations/
The MATH+ Hospital Treatment Protocol for COVID-19 is designed for hospitalized patients, to be initiated as soon as possible after they develop respiratory difficulty and require oxygen supplementation. The three core pathophysiologic processes that have been identified are severe hypoxemia, hyperinflammation, and hypercoagulability. This combination medication protocol is designed to counteract these processes either through the use of single agents or in synergistic actions. A unique insight into this disease made by members of our group is that the majority of patients initially present with an inflammatory reaction in the lungs called “organizing pneumonia,” which is the body’s reaction to injury and is profoundly responsive to corticosteroid therapy. If the organizing pneumonia response is left untreated or presents as a rapidly progressive sub-type, a condition called Acute Respiratory Distress Syndrome (ARDS) follows.
The two main therapies that can reverse and/or mitigate the extreme inflammation causing ARDS are the combination of the corticosteroid Methylprednisolone and the antioxidant Ascorbic acid, which is given intravenously and in high doses. Both of these medicines have multiple synergistic physiologic effects and have been shown in multiple randomized controlled trials to improve survival in ARDS, particularly when given early in the disease. Thiamine is given to optimize cellular oxygen utilization and energy consumption, protecting the heart, brain, and immune system. Given the numerous clinical and scientific investigations that have demonstrated consistent, reproducible, and excessive levels of hyper-coagulation, particularly in the severely ill, the anticoagulant Heparin is used to both prevent and help in dissolving blood clots that appear with a very high frequency. The “+” sign indicates several important co-interventions that have a combination of strong physiologic rationale with existing or emerging pre-clinical and clinical data to support their use in similar conditions or in COVID-19 itself, and all with a well-established safety profile. Such adjunctive therapies are continuously being evaluated and amended as the published medical evidence evolves.
Timing is a critical factor in the efficacy of MATH+ and to achieving successful outcomes in patients ill with COVID-19. Patients must go to the hospital as soon as they experience difficulty breathing or have a low oxygen level. The MATH+ protocol should be administered soon after a patient meets criteria for oxygen supplementation (within the first hours after arrival in the hospital), in order to achieve maximal efficacy. Delayed therapy can lead to complications such as the need for mechanical ventilation. If administered early, the MATH+ formula of FDA-approved, safe, inexpensive, and readily available drugs may eliminate the need for ICU beds and mechanical ventilators and return patients to health.
Jan 17, 2021 | PUBLIC STATEMENT
FLCCC Alliance Response to the NIH Guideline Committee Recommendation on Ivermectin use in COVID-19 dated January 14th, 2021
https://player.vimeo.com/video/490351508?dnt=1&app_id=122963
Dr. Pierre Kory testifies to Senate Committee about Ivermectin, Dec. 8, 2020
Appearing as a witness on Dec. 8, 2020, before the Senate Committee on Homeland Security and Governmental Affairs—which held a hearing on “Early Outpatient Treatment: An Essential Part of a COVID-19 Solution”— Dr. Pierre Kory, President of the Frontline COVID-19 Critical Care Alliance (FLCCC), called for the government to swiftly review the already expansive and still rapidly emerging medical evidence on Ivermectin. Read More
Jan 7, 2021 – Press Release
FLCCC Alliance Invited to the NIH COVID-19 Treatment Guidelines Panel to Present Latest Data on Ivermectin
On January 6, 2021, our Drs. Pierre Kory and Paul Marik, founding members of the FLCCC Alliance, appeared before the National Institutes of Health COVID-19 Treatment Guidelines Panel to urge review of current data and an updated NIH guidance.
Dec 15, 2020 – now published:
Clinical and Scientific Rationale for the “MATH+” Hospital Treatment Protocol for COVID-19
FLCCC Alliance peer-reviewed paper published in the Journal of Intensive Care Medicine. The protocol described in this paper potentially offers a life-saving approach to the management of hospitalized COVID-19 patients. The MATH+ protocol offers an inexpensive combination of medicines with well-known safety profiles based on strong physiologic rationale and an increasing clinical evidence base.
“The I-MASK+ protocol will revolutionize the treatment of COVID-19”
Dr. Paul Marik (Oct. 30, 2020)
The Front Line COVID-19 Critical Care Alliance has now developed a prophylactic and early outpatient combination treatment protocol for COVID-19 called I-Mask+. This protocol is centered around the use of ivermectin, a well-known anti-parasite drug. Ivermectin has recently discovered anti-viral and anti-inflammatory properties and a rapidly growing published medical evidence base demonstrating its unique and highly potent ability to inhibit SARS-CoV-2 replication.
Please visit these links to get the full picture:
- I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19
- Our comprehensive review of the emerging evidence for Ivermectin use in our I-MASK+ protocol
- A one-page summary of the scientific review on ivermectin above
- Dr. Paul Marik’s comprehensive meta-analysis of COVID-19 therapeutics
- An introductory video explaining the review on Ivermectin by Dr. Pierre Kory
- Dr. Paul Marik’s recent lecture on I-MASK+
- Invited Grand Rounds Lecture on ivermectin by Pierre Kory
In March, 2020 we first published our MATH+ Treatment Protocol for COVID-19, intended for hospitalized patients. The recently developed I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 is instead directed for use as a prophylaxis and in early outpatient treatment after contracting COVID-19. The protocols thus complement each other, and both are physiologic-based combination treatment regimens developed by leaders in critical care medicine. All component medicines are FDA-approved (except ivermectin), inexpensive, readily available and have been used for decades with well-established safety profiles.
- An FLCCC Alliance guide to the management of COVID-19 – An overview of the MATH+ and I-MASK+ protocols
Greg Larsen with his brother Early Nov 2020
RNA virus: A virus in which the genetic material is RNA. The RNA may be either double- or single-stranded. … Class IV viruses have a positive single-stranded RNA genome, the genome itself acting as mRNA (messenger RNA. Class V viruses have a negative single-stranded RNA genome used as a template for mRNA synthesis.
**UPDATE** Please scroll down for recommendations on nutritional supplements and holistic approaches to boost your immune system!
Viruses are smaller than bacteria and can’t survive without a living host. A virus attaches itself to cells and usually reprograms them to reproduce itself. Also, unlike bacteria, most viruses do cause disease. Some virus-caused diseases include the common cold, AIDS, herpes, and chickenpox.
Coronaviruses have helically symmetrical nucleocapsids, which is uncommon among positive-sense RNA viruses, but far more common for negative-sense RNA viruses. Coronavirus virus particles contain four main structural proteins. … The M protein is the most abundant structural protein in the virion.
Negative-sense ssRNA viruses (Group V) must have their genome copied by an RNA replicase to form positive-sense RNA. This means that the virus must bring along with it the RNA replicase enzyme. The positive-sense RNA molecule then acts as viral mRNA, which is translated into proteins by the host ribosomes.
Read More
